Home › Neuroblastoma › New Jersey
Neuroblastoma clinical trials in New Jersey
6 studies for Neuroblastoma are looking for participants at sites in New Jersey.
Cities in New Jersey
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Saint Peter's University Hospital, New Brunswick
- and 3 more
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 2, 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Saint Peter's University Hospital, New Brunswick
- and 3 more
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
- Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent Only), Middletown
- Memorial Sloan Kettering Bergen (Consent Only), Montvale
RecruitingPhase 2
All ages · All sexes · Updated Jul 28, 2026 · NCT06057948From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.